Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Losartan in diabetic nephropathy.

Norberto Perico1, Piero Ruggenenti, Giuseppe Remuzzi

  • 1Department of Medicine and Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. perico@marionegri.it <perico@marionegri.it>

Expert Review of Cardiovascular Therapy
|July 1, 2004
PubMed
Summary

Diabetic nephropathy, a leading cause of kidney failure, can be managed by targeting the renin-angiotensin system. Losartan, an angiotensin-type 1 receptor blocker, effectively slows diabetic nephropathy progression in Type 2 diabetes patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Journal of the American Society of Nephrology : JASN·2015
Same author

International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology.

Lancet (London, England)·2015
Same author

Rare diseases and effective treatments: are we delivering?

Lancet (London, England)·2015
Same author

Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts.

Stem cell reports·2015
Same author

Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury.

Scientific reports·2015
Same author

Need for chronic kidney disease prevention programs in disadvantaged populations.

Clinical nephrology·2015

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Diabetic nephropathy is a primary cause of end-stage renal disease globally.
  • Proteinuria severity predicts renal function decline and treatment efficacy.
  • The renin-angiotensin system is a key target for renoprotection in proteinuric nephropathies.

Purpose of the Study:

  • To evaluate the renoprotective effects of losartan, an angiotensin-type 1 receptor blocker, in patients with diabetic nephropathy.
  • To assess losartan's efficacy in slowing the progression of overt Type 2 diabetic nephropathy.

Main Methods:

  • Review of experimental and clinical observations on renin-angiotensin system blockade.
  • Analysis of short-term studies in Type 1 and Type 2 diabetic patients.

Related Experiment Videos

  • Evaluation of data from the Reduction of End points in Noninsulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial.

    • Main Results:

    • Losartan demonstrated beneficial effects on albumin excretion rate, blood pressure, and renal hemodynamics in Type 1 and Type 2 diabetic patients.
    • Blockade of angiotensin-type 1 receptor with losartan was superior to conventional antihypertensive therapy in slowing overt Type 2 diabetic nephropathy progression.
    • Losartan also showed efficacy in microalbuminuric patients with Type 2 diabetes.

    Conclusions:

    • Angiotensin-type 1 receptor blockers, including losartan, are beneficial in preventing and managing diabetic renal disease progression.
    • Further implementation of angiotensin-type 1 receptor antagonists in multidrug approaches may enhance renoprotection for diabetic patients with chronic nephropathy.